Details

Ectoparasites


Ectoparasites

Drug Discovery Against Moving Targets
Drug Discovery in Infectious Diseases 1. Aufl.

von: Charles Q. Meng, Ann E. Sluder, Paul M. Selzer

133,99 €

Verlag: Wiley-VCH
Format: EPUB
Veröffentl.: 01.06.2018
ISBN/EAN: 9783527802890
Sprache: englisch
Anzahl Seiten: 720

DRM-geschütztes eBook, Sie benötigen z.B. Adobe Digital Editions und eine Adobe ID zum Lesen.

Beschreibungen

This first book specifically dedicated to ectoparasite drug discovery is unique in providing insights from the veterinary as well as the medical perspective, covering research from both industry and academia while paving the way for new synergies between the two research communities. Edited by a team combining 80 years of experience in academic research and industrial antiparasitic drug discovery, this volume of Drug Discovery in Infectious Diseases summarizes current knowledge in this rapidly expanding field. Comprehensive yet concise, this ready reference blends solid background information on ectoparasite biology with the very latest methods in ectoparasite drug discovery. Three major parts cover current ectoparasite control strategies and the threat of drug resistance, screening and drug evaluation, and the new isoxazoline class of ectoparasiticides. The future potential of mechanism-based approaches for repellents and parasiticides is thoroughly discussed, as are strategies for vaccines against ectoparasites, making the book ideal for parasitologists in academia as well as researchers working in the pharmaceutical industry.
PART I: NEED AND OPPORTUNITY IN ECTOPARASITE DRUG DISCOVERY Challenges in preventing & treating ectoparasite infestations in human and animal health Overview of major ectoparasites of humans and animals Existing ectoparasite therapies in animal health and their extension to human health The threat and reality of drug resistance PART II: DISCOVERY SCREENING APPROACHES Whole organism screens for ectoparasiticides Repellency screens Animal models Testing repellents in humans PART III: MOLECULAR TARGETS Neuromuscular excitation and targets for knock-down parasiticides Octopamine and tyramine receptors in acarids The elusive DEET receptor Ectoparasite odorant receptors as repellency targets PART IV: NEW DEVELOPMENTS Isoxazolines Other chemical series in development Anti-tick vaccines: Failed promise or unrealized opportunity?
Dr. Charles Q. Meng earned his PhD degree in Organic Chemistry from the University of Zurich in 1991. Upon completing postdoctoral research at Roche (Basel) and the University of Montreal he worked for Allelix Biopharmaceuticals (Mississauga, Ontario) on migraine drug discovery and AtheroGenics (Alpharetta, Georgia) on cardiovascular drug discovery. In 2007 Dr. Meng joined the pharmaceutical discovery and research group of Merial, a Sanofi company then and part of Boehringer Ingelheim now, focusing on antiparasitic drug discovery for animal health. He is an inventor of 25 issued US patents and an author of over 30 publications of original research, reviews, commentaries and book chapters. Dr. Ann E. Sluder earned a PhD in Biochemistry from Duke University in 1988 studying transcription biochemistry in Drosophila melanogaster. During postdoctoral studies at Harvard Medical School and Massachusetts General Hospital she initiated a research program focused on nuclear receptor transcription factors in the nematode Caenorhabditis elegans, which she expanded to include parasitic nematodes while an Assistant Professor of Cellular Biology at the University of Georgia. From 2000-2014 Dr. Sluder worked in drug discovery for antiparasitics, orphan neuromuscular diseases and viral and fungal infections at two biotechnology companies. In 2015 she joined the Vaccine and Immunotherapy Center of the Massachusetts General Hospital, managing preclinical development programs in infectious diseases, cancer, and diabetes. Prof. Dr. Paul M. Selzer studied Biology, Parasitology, and Biochemistry at the University of Tubingen, Germany, where he also received his PhD in Biochemistry. He spent three years at the Molecular Design Institute and the Tropical Disease Research Laboratory at the University of California, San Francisco. During his career he has worked as a researcher and scientific manager for several pharmaceutical companies, and is currently holding the position of Head Antiparasitics R&D at Boehringer Ingelheim Animal Health. He is also a visiting professor at the Interfaculty Institute of Biochemistry of the University of Tubingen, DE and an honorary professor of the Department of Infection, Immunity, and Inflammation at the University of Glasgow, UK.